Narlumosbart
Phase 3Small molecule
Narlumosbart is one of 89 small molecule programs targeting NSCLC. It is currently in Phase 3.
3
Indications
3
Total Trials
3
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Cytosar
TevaPhase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Etentamig
AbbViePhase 3
Granulocyte Colony-Stimulating Factor
SanofiPhase 3
Daratumumab SC
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Giant Cell Tumor1 trial
Multiple Myeloma1 trial
NSCLC1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Narlumosbart. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShanghai JMT-Bio Inc.